These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25432394)

  • 1. New therapies for reducing low-density lipoprotein cholesterol.
    Stein EA; Raal FJ
    Endocrinol Metab Clin North Am; 2014 Dec; 43(4):1007-33. PubMed ID: 25432394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Other therapies for reducing low-density lipoprotein cholesterol: medications in development.
    Stein EA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):99-119. PubMed ID: 19217514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.
    El Harchaoui K; Akdim F; Stroes ES; Trip MD; Kastelein JJ
    Am J Cardiovasc Drugs; 2008; 8(4):233-42. PubMed ID: 18690757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs.
    López-Miranda J; Pedro-Botet J
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():46-52. PubMed ID: 33966813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins: safety and pharmacological interactions.
    Di Girolamo G; González C
    Expert Opin Drug Saf; 2012 Nov; 11(6):889-91. PubMed ID: 23043327
    [No Abstract]   [Full Text] [Related]  

  • 10. The power of statins: aggressive lipid lowering.
    Jones PH
    Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol: how low can we go?
    Sherbet DP; Garg P; Brilakis ES; Banerjee S
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 13. New pharmacologic treatments for familial hypercholesterolemia.
    McDonough A; Matura LA; Carroll D
    Nurs Womens Health; 2013 Oct; 17(5):443-7. PubMed ID: 24138664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
    Ricotta DN; Frishman W
    Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
    Doggrell SA
    Complement Ther Med; 2011 Feb; 19(1):37-46. PubMed ID: 21296266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do statins decrease cardiovascular disease at the expense of increasing cancer?
    Goldstein MR; Mascitelli L
    Int J Cardiol; 2009 Apr; 133(2):254-5. PubMed ID: 18164769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis.
    Delahoy PJ; Magliano DJ; Webb K; Grobler M; Liew D
    Clin Ther; 2009 Feb; 31(2):236-44. PubMed ID: 19302897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.